Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development

Go back to Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development
METABASIS THERAPEUT (NASDAQ: MBRX) Delayed: 8.06 +0.97 (13.68%)
Previous Close $7.09    52 Week High $9.58 
Open $7.18    52 Week Low $2.34 
Day High $8.06    P/E N/A 
Day Low $7.17    EPS $-0.34 
Volume 13,740